These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16042369)

  • 1. Transdermal androgens: pharmacology and applicability to hypogonadal elderly men.
    Swerdloff RS; Wang C
    J Endocrinol Invest; 2005; 28(3 Suppl):112-6. PubMed ID: 16042369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
    Swerdloff RS; Wang C
    Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone treatment in elderly men.
    Srinivas-Shankar U; Sharma D
    Adv Ther; 2009 Jan; 26(1):25-39. PubMed ID: 19198768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal delivery of testosterone.
    Hadgraft J; Lane ME
    Eur J Pharm Biopharm; 2015 May; 92():42-8. PubMed ID: 25709060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to: Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Morgentaler A
    Int J Impot Res; 2008; 20(3):331; author reply 332. PubMed ID: 18475269
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.
    Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E
    Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
    Asscheman H; Gooren LJ
    Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Ebert T, Jockenhövel F, Morales A, Shabsigh R. The current status of therapy for symptomatic late onset hypogonadism with transdermal testosterone gel. Eur Urol 2005;47:137-46.
    Ponholzer A; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):170-1; author reply 171. PubMed ID: 15967269
    [No Abstract]   [Full Text] [Related]  

  • 15. [Should older men be treated with testosterone?].
    Svartberg J
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):879-82. PubMed ID: 15815734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW; Matthias D; Hoffman AR
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring androgen replacement therapy: testosterone and prostate safety.
    Morales A
    J Endocrinol Invest; 2005; 28(3 Suppl):122-7. PubMed ID: 16042371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score.
    Chiang HS; Cho SL; Lin YC; Hwang TI
    Urology; 2009 Apr; 73(4):762-6. PubMed ID: 19118875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.